These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2582777)

  • 21. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study.
    Cheng IK; Cy C; Chan MK; Yu L; Fang GX; Wei D
    Clin Nephrol; 1991 May; 35(5):207-12. PubMed ID: 1855328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous recombinant human erythropoietin in children with renal anemia on continuous ambulatory peritoneal dialysis.
    Aufricht C; Balzar E; Steger H; Lothaller MA; Frenzel K; Kohlhauser C; Kiss H; Khoss AE; Kernova T
    Acta Paediatr; 1993 Nov; 82(11):959-62. PubMed ID: 8111178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.
    Nicholas JC
    Drugs Aging; 2004; 21(3):187-201. PubMed ID: 14979736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One year experience with subcutaneous human erythropoietin in CAPD: correction of renal anemia and increased ultrafiltration.
    Lubrich-Birkner I; Schollmeyer P; Steinhauer HB
    Adv Perit Dial; 1990; 6():302-7. PubMed ID: 1982833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.
    Marsden JT; Sherwood RA; Hillis A; Peters TJ
    Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():205-6. PubMed ID: 8466156
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of erythropoietin in the reversal of anemia of renal failure with continuous ambulatory peritoneal dialysis.
    Chandra M; McVicar M; Clemons G; Mossey RT; Wilkes BM
    Nephron; 1987; 46(3):312-5. PubMed ID: 3627325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased ultrafiltration after erythropoietin-induced correction of renal anemia in patients on continuous ambulatory peritoneal dialysis.
    Steinhauer HB; Lubrich-Birkner I; Dreyling KW; Hörl WH; Schollmeyer P
    Nephron; 1989; 53(1):91-2. PubMed ID: 2779711
    [No Abstract]   [Full Text] [Related]  

  • 28. Practical guidelines for the use of NESP in treating renal anaemia.
    Aljama P; Bommer J; Canaud B; Carrera F; Eckardt KU; Hörl WH; Krediet RT; Locatelli F; Macdougall IC; Wikström B;
    Nephrol Dial Transplant; 2001; 16 Suppl 3():22-8. PubMed ID: 11402087
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.
    Hussein MM; Mooij JM; Roujouleh H
    Nephrol Dial Transplant; 1994; 9(7):876-7. PubMed ID: 7818713
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of renal anemia with intravenous erythropoietin in patients in the program of continuous ambulatory peritoneal dialysis].
    Zelichowski G; Lubas A; Sienkiewicz M; Janusz E; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):312-5. PubMed ID: 18634362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme.
    Almond MK; Tailor D; Marsh FP; Raftery MJ; Cunningham J
    Nephrol Dial Transplant; 1994; 9(3):270-3. PubMed ID: 8052433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of renal anemia with recombinant human erythropoietin.
    Schaefer RM; Hörl WH; Massry SG
    Am J Nephrol; 1989; 9(5):353-62. PubMed ID: 2679093
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of human recombinant erythropoietin on plasminogen activator inhibitor, and protein C and S activity.
    Steffensen G; Aunsholt NA
    Am J Nephrol; 1996; 16(5):453-4. PubMed ID: 8886186
    [No Abstract]   [Full Text] [Related]  

  • 34. Once-weekly epoetin-beta in renal anemia: the clinical evidence.
    Albertazzi A
    Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986
    [No Abstract]   [Full Text] [Related]  

  • 35. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
    Díez J; Iglesias P; Sastre J; Méndez J; Selgas R; Gómez-Pan A
    Nephron; 1996; 74(3):548-54. PubMed ID: 8938679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment.
    Hughes RT; Cotes PM; Pippard MJ; Stevens JM; Oliver DO; Winearls CG; Royston JP
    Br J Haematol; 1990 Jun; 75(2):268-73. PubMed ID: 2372513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin for chronic ambulatory peritoneal dialysis patients: once a week can be enough.
    Hood VL; Ingraham A
    J Am Soc Nephrol; 1992 Apr; 2(10):1545-6. PubMed ID: 1600126
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of erythropoietin on anaemia in patients with myeloma receiving haemodialysis.
    Taylor J; Mactier RA; Stewart WK; Henderson IS
    BMJ; 1990 Sep; 301(6750):476-7. PubMed ID: 2207402
    [No Abstract]   [Full Text] [Related]  

  • 40. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
    Macdougall IC; Matcham J; Gray SJ;
    Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.